Medically reviewed by Christine L. Larsen, MD Myopic macular degeneration (MMD), or pathological myopia, occurs when high ...

The FDA has asked for another well-controlled trial to establish the efficacy of reproxalap in dry eye disease.

Five years from the start of the COVID-19 pandemic, numerous academic studies have shown how the novel coronavirus affects ocular health.

Bryan Wolynski, a board-certified optometrist, discusses what patients should know before their first appointment for ...

As we approach World Health Day (Monday 7 April), it’s an ideal opportunity to turn inwards and check on our own health and ...

In today’s digitally driven world, the average person spends a significant portion of their day looking at screens—phones, ...

As the pollen count continues to rise, a pharmacist has shared his tips on how to tackle eye health issues when pollen ...

Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease. The ...

The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...

The Company expects to have topline data from 2 trials assessing the effect of reproxalap on dry eye disease symptoms available in the second quarter of 2025.

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish ...

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive ...